Nuclear Medicine & Radiation Therapy

ISSN: 2155-9619

Open Access

Tiancheng Zhang

Key Laboratory of Medical Epigenetics and Metabolism, Institutes of Biomedical Sciences, Fudan University, Shanghai, China

  • Mini Review   
    Resistant Regulatory Results of Molecularly Selected Therapy and its Repurposed Applications in Cancer Immunotherapy
    Author(s): Tiancheng Zhang*

    The quick development of hostile to growth specialists encapsulates a more profound comprehension of disease pathogenesis. Until this point, chemotherapy, designated treatment, and immunotherapy are three mainstays of the world view for malignant growth treatment. The outcome of safe designated spot inhibitors (ICIs) infers thatrestoration of insusceptibility can effectively control cancer development, attack, and metastasis. Be that as it may, just a small portion of patients benefit from ICI treatment, which turns the focus on creating safe restorative procedures to beat the issue of an unsuitable reaction. Sub-atomic designated specialists were intended to kill disease cells with oncogenic transformations or transcriptional targets. Intriguingly, amassing smidgens of proof exhibit the immunostimulatory or immunosuppressive limit of designated specialists. By.. Read More»
    DOI: 10.37421/2155-9619.2022.13.495

    Abstract HTML PDF

Google Scholar citation report
Citations: 706

Nuclear Medicine & Radiation Therapy received 706 citations as per Google Scholar report

Nuclear Medicine & Radiation Therapy peer review process verified at publons

Indexed In

arrow_upward arrow_upward